MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
Exploring the companies and themes that make up this emerging and exciting new sector
MindMed Closes on Upsized Financing of $13.2m
MindMed has issued 24.95 million units at a unit price of CAD$0.53.
Dr. Gabor Maté joins Numinus as Member of the Clinical Advisory Council
Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community.
Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer
Numinus names a new Chief Medical Officer.
Numinus Takes Off On Initial Day Of Trading
Numinus Wellness is a new psychedelics stock that is up over 300% on its initial day of trading.